A mutant form of NRP2 (MutB-NRP2) that acts as a decoy and binds to VEGF with eightfold increased affinity compared with wild-type NRP2 reduced tumor burden in a xenograft model using melanoma cells, alone and when used in combination with bevacizumab (280, 281). Here, NRP2 is linked to melanoma.